DNA Vaccines—How Far From Clinical Use?

Abstract

Two decades ago successful transfection of antigen presenting cells (APC) in vivo was demonstrated which resulted in the induction of primary adaptive immune responses. Due to the good biocompatibility of plasmid DNA, their cost-efficient production and long shelf life, many researchers aimed to develop DNA vaccine-based immunotherapeutic strategies for treatment of infections and cancer, but also autoimmune diseases and allergies. This review aims to summarize our current knowledge on the course of action of DNA vaccines, and which factors are responsible for the poor immunogenicity in human so far. Important optimization steps that improve DNA transfection efficiency comprise the introduction of DNA-complexing nano-carriers aimed to prevent extracellular DNA degradation, enabling APC targeting, and enhanced endo/lysosomal escape of DNA. Attachment of virus-derived nuclear localization sequences facilitates nuclear entry of DNA. Improvements in DNA vaccine design include the use of APC-specific promotors for transcriptional targeting, the arrangement of multiple antigen sequences, the co-delivery of molecular adjuvants to prevent tolerance induction, and strategies to circumvent potential inhibitory effects of the vector backbone. Successful clinical use of DNA vaccines may require combined employment of all of these parameters, and combination treatment with additional drugs.

In Vivo Assembly of Nanoparticles Achieved through Synergy of Structure‐Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity

“…Particulate vaccine formulations can help boost immunogenicity but can be slow to develop on a large scale due to manufacturing complexities. Synthetic nucleic‐acid‐based methods for the delivery of vaccine antigens have shown great promises, as they are often produced at significantly lower costs than their protein counterparts, can be manufactured to scale and bypass complex processes of assembly,49 offer superior safety profile,50 and demonstrate remarkable thermostability to allow for extended shelf‐lives 51…”

Global efforts on vaccines for COVID-19: Since, sooner or later, we all will catch the coronavirus

“…In this case, the DNA sequence is introduced, often facilitated by nano-carriers, directly to the cells of a specific tissue. Once they make their way into the nucleus with the help of a targeting sequence, viral surface protein production, driven from an optimized promoter, is outsourced to the host cells natural machinery (Hobernik and Bros 2018). DNA vaccines are safe, stable and large quantities can be produced in a short time through cost-effective manufacturing processes, which is crucial for distribution in low-income regions.…”

Mesenchymal Stem Cells Beyond Regenerative Medicine

“…In addition to intact antigenic peptides, alternative vaccines exist, such as in situ antigen production or presentation using plasmid vectors (DNA) and antigen-pulsed host cells (APCs, MSCs). However, they have not yet achieved any clinical benefits, mainly due to their low immunogenicity (MacGregor et al, 1998;Tomchuck et al, 2012;Hobernik and Bros, 2018).…”